+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 1352226-88-0
1352226-88-0,MFCD29472273
Catalog No.:AA009CE6

1352226-88-0 | AZD6738

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$24.00   $17.00
- +
2mg
98%
in stock  
$39.00   $28.00
- +
50mg
98%
in stock  
$224.00   $157.00
- +
100mg
98%
in stock  
$368.00   $258.00
- +
250mg
98%
in stock  
$591.00   $414.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA009CE6
Chemical Name:
AZD6738
CAS Number:
1352226-88-0
Molecular Formula:
C20H24N6O2S
Molecular Weight:
412.5086
MDL Number:
MFCD29472273
SMILES:
C[C@@H]1COCCN1c1cc(nc(n1)c1ccnc2c1cc[nH]2)C1(CC1)S(=O)(=N)C
Properties
Computed Properties
 
Complexity:
724  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
4  
XLogP3:
2.6  

Downstream Synthesis Route

[1]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[2]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[1]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[2]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[3]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[1]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[2]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[1]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[2]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[3]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[1]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[2]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[3]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[4]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[5]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[6]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[7]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

[8]CurrentPatentAssignee:PFIZERINC;TAKEDAPHARMACEUTICALCOMPANYLIMITED;ASTRAZENECAPLC-US2011/306613,2011,A1

Literature

Title: The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.

Journal: Oncotarget 20151229

Title: Vendetti FP, et al. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of CDDP to resolve ATM-deficient non-small cell lung cancer in vivo.

Title: Kim HJ, et al. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Int J Cancer. 2017 Jan 1;140(1):109-119.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1352226-88-0
1233339-22-4

1233339-22-4

 1352226-97-1

1352226-97-1

 1352232-89-3

1352232-89-3
Building Blocks
More >
Tags:1352226-88-0 Molecular Formula|1352226-88-0 MDL|1352226-88-0 SMILES|1352226-88-0 AZD6738